Asset Details
Do you wish to reserve the book?
Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (neoral)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (neoral)
Do you wish to request the book?
Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (neoral)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (neoral)
2006
Overview
BackgroundIntravenous cyclosporine is active in 60% to 80% of patients with ulcerative colitis (UC) who failed to respond to intravenous corticosteroids. Several studies have suggested that cyclosporine in microemulsion form (Neoral) has some efficacy in this setting, but the optimal dose, blood level, time to response, and remission need to be better defined. The aim of this study was to evaluate the response to Neoral and its toxicity in active corticosteroid-refractory UC.MethodsBetween March 2002 and August 2005, 20 courses of Neoral [initial dose, 2.3 mg/kg (range, 1.8 to 2.8 mg/kg) every 12 hours] were prescribed in 19 consecutive patients for a UC attack that did not respond to intravenous methylprednisolone. All patients received prophylaxis against Pneumocystis carinii.ResultsResponse was obtained in 17 of 20 attacks (85%) after 3.5 days (range, 1 to 7). Remission was obtained in 15 of 20 attacks (75%) after 13 days (range, 2 to 30 days). Four responders relapsed and underwent colectomy 21 to 900 days after the start of Neoral. Overall, 14 of 19 patients (74%) were colectomy free after a median follow-up of 8 months (range, 1 to 41 months). Cyclosporine blood levels were measured at fasting (C0) and 2 hours after Neoral administration (C2) in a subgroup of 10 responders. The results were 103 ng/mL (range, 32 to 240 ng/mL) for C0 and 761 ng/mL (183 to 1390 ng/mL) for C2. One severe bedridden patient with neonatal encephalopathy died. Main side effects observed were mild transient renal impairment (n = 2), hypertension (n = 1), cytomegalovirus infection (n = 2), and esophageal candidiasis (n = 1).ConclusionsIn active corticosteroid-refractory UC, Neoral seems to have the same efficacy and toxicity as the intravenous form. Trough target cyclosporine blood levels should not exceed 100 ng/mL for C0 and 700 ng/mL for C2.
Publisher
Oxford University Press,Lippincott Williams & Wilkins, Inc,Lippincott, Williams & Wilkins
Subject
/ Adrenal Cortex Hormones - therapeutic use
/ Adult
/ Aged
/ Colitis, Ulcerative - drug therapy
/ Cyclosporine - administration & dosage
/ Cyclosporine - adverse effects
/ Cyclosporine - therapeutic use
/ Fasting
/ Female
/ Humans
/ Hépatology and Gastroenterology
/ Immunosuppressive Agents - adverse effects
/ Immunosuppressive Agents - blood
/ Immunosuppressive Agents - therapeutic use
/ Kidney
/ Male
/ Neonates
/ Steroids
/ Toxicity
